EDP-297: A Novel, Highly Potent, Farnesoid X Receptor Agonist: Results of a Phase 1 Study in Healthy Subjects
A Novel FXR Agonist EDP-297 Exerts Anti-Inflammatory and Hepatoprotective Effects in Human Liver 3D Microtissues and in Rodent Models of Liver Injury and NASH
EDP-297, A Novel and Potent FXR Agonist, Exhibits Robust Anti-Fibrotic Effects with Significant Liver Function Improvement in a Rat Model of Non-Alcoholic Steatohepatitis
EP-024297, A Novel and Selective Farnesoid X Receptor Agonist, Exhibits High Potency and Efficacy In Vitro and In Vivo